
Claims

1. Use of an antibody-drug conjugate in the manufacture of a medicament for treating cancer, wherein
the antibody-drug conjugate and a tubulin inhibitor are to be administered in combination, and
the antibody-drug conjugate is an antibody-drug conjugate in which a drug-linker represented by the following formula is conjugated to the antibody via a thioether bond:



wherein A represents a connecting position to an antibody;

wherein the antibody is an anti-HER2 antibody comprising a heavy chain consisting of amino acid residues 1 to 449 of SEQ ID NO: 1 and a light chain consisting of amino acid residues 1 to 214 of SEQ ID NO: 2, or wherein the antibody is an anti-HER2 antibody comprising a heavy chain consisting of an amino acid

sequence represented by SEQ ID NO: 1 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 2; and

wherein the tubulin inhibitor is paclitaxel, docetaxel, cabazitaxel, or a pharmacologically acceptable salt thereof; nab-paclitaxel; eribulin or a pharmacologically acceptable salt thereof; or an antibody-drug conjugate in which eribulin is conjugated to the antibody via a linker.

2. Use according to claim 1, wherein the anti-HER2 antibody comprises a heavy chain consisting of amino acid residues 1 to 449 of SEQ ID NO: 1 and a light chain consisting of amino acid residues 1 to 214 of SEQ ID NO: 2.

3. Use according to claim 1, wherein the anti-HER2 antibody comprises a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 1 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 2.

4. Use according to any one of claims 1 to 3, wherein the average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate is in the range of from 7 to 8.

5. Use according to any one of claims 1 to 4, wherein the tubulin inhibitor is paclitaxel, docetaxel, cabazitaxel, or a pharmacologically acceptable salt thereof, or nab-paclitaxel.

6. Use according to claim 5, wherein the tubulin inhibitor is paclitaxel.

7. Use according to any one of claims 1 to 4, wherein the tubulin inhibitor is eribulin or a pharmacologically acceptable salt thereof, or an antibody-drug conjugate in which eribulin is conjugated to the antibody via a linker.

8. Use according to claim 7, wherein the tubulin inhibitor is eribulin mesylate.

9. Use according to any one of claims 1 to 8, wherein the antibody-drug conjugate and the tubulin inhibitor are separately contained as active components in different formulations, and are to be administered simultaneously or at different times.

10. Use according to any one of claims 1 to 9, wherein the cancer is at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, salivary gland

cancer, esophagogastric junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, and uterine carcinosarcoma.

11. Use according to claim 10, wherein the cancer is breast cancer.

12. Use according to claim 10, wherein the cancer is gastric cancer.

13. Use according to claim 10, wherein the cancer is lung cancer.

14. Use according to claim 10, wherein the cancer is ovarian cancer.